

Methylphenidate and Its Salts

Methylphenidate and its salts, such as methylphenidate hydrochloride (Ritalin), are commonly prescribed psycho-stimulants used in the treatment of attention deficit/hyperactivity disorder in children and adults. Methylphenidate is also used to treat narcolepsy.

Methylphenidate and its salts passed the animal data screen, underwent a preliminary toxicological evaluation, and are being brought to the Carcinogen Identification Committee for consultation. This is a compilation of the relevant studies identified during the preliminary toxicological evaluation.

Epidemiological data

- Cohort studies
 - Members of Kaiser Permanente health plan in the San Francisco Bay Area and Central California, 1991 – 2003 (35,400 methylphenidate users under the age of 20 years): Oestreicher *et al.* (2007)
 - *Elevated standardized morbidity ratio for lymphocytic leukemia in child methylphenidate users*
 - Members of Kaiser Permanente health plan in the San Francisco Bay Area, 1969 – 1973 (529 methylphenidate users of any age): Selby *et al.* (1989)
 - *No increase in cancer risk in subjects receiving methylphenidate*

Animal carcinogenicity data

- Two-year dietary studies
 - Male and female B6C3F₁ mice: NTP (1995)
 - *Liver tumors (by pairwise comparison and trend) in males and females*
 - Male and female F344/N rats: NTP (1995)
 - *No treatment-related tumor findings*
- Transgenic mouse studies
 - 24-week dietary studies in male and female transgenic p53(+/-) mice: Freeman *et al.* (1998)
 - *No treatment-related tumor findings*
 - 24-week dietary studies in male and female Tg.AC transgenic mice: Freeman *et al.* (1998)
 - *No treatment-related tumor findings*

Other relevant data

- Genotoxicity
 - SCE, CA, and MN in lymphocytes of exposed children (*positive and negative*): El-Zein *et al.* (2005); Witt *et al.* (2008); Ponsa *et al.* (2009); Walitza *et al.* (2010)
 - DNA damage in rat cells *in vivo* (*positive and negative*): Andreatza *et al.* (2007); Witt *et al.* (2010)
 - Sister chromatid exchanges (SCE) and chromosome aberrations (CA) in Chinese hamster ovary cells (*positive*): NTP (1995, p. 5, 56); NTP (2005, pp. II-34 – II-35)
 - Mutagenicity in *S. typhimurium* (*negative*): NTP (1995, p.7, 56); NTP (2005, pp. II-34 – II-35)
 - Mutagenicity in *E. coli* (*negative*): NTP (2005, pp. II-34 – II-35)
 - Mutagenicity in mouse lymphoma cells (*negative*): NTP (2005, pp. II-34 – II-35)
 - Induction of unscheduled DNA synthesis in rat hepatocytes *in vitro* (*negative*): Mirsalis *et al.* (1983)
 - Transformation assay in BALB/c-3T3 cells (*negative*): NTP (2005, pp. II-35)
 - Mutations in Big Blue mice *in vivo* (*negative*): Manjanatha *et al.* (2009)
 - HIS49 Pig-A mutations in red blood cells of rats exposed *in vivo* (*negative*): Dobrovolsky *et al.* (2010)
 - Micronuclei (MN) in mouse bone marrow and peripheral blood erythrocytes *in vivo* (*negative*): NTP (2005, p. II-35); Manjanatha *et al.* (2009)
 - MN in rat blood cells *in vivo* (*negative*): Andreatza *et al.* (2007); Dobrovolsky *et al.* (2010); Witt *et al.* (2010)
 - HPRT mutation, MN, and CA in male rhesus monkeys *in vivo* (*negative*): Morris *et al.* (2009)

- Mechanistic considerations
 - CA as a biomarker of cancer risk: Bonassi *et al.* (2008)

References¹

Andreatza AC, Frey BN, Valvassori SS, Zanotto C, Gomes KM, Comim CM, Cassini C, Stertz L, Ribeiro LC, Quevedo J, Kapczinski F, Berk M, Gonçalves CA (2007). DNA damage in rats after treatment with methylphenidate. *Prog Neuropsychopharmacol Biol Psychiatry* **31**:1282-8.

Bonassi S, Norppa H, Ceppi M, Strömberg U, Vermeulen R, Znaor A, Cebulska-Wasilewska A, Fabianova E, Fucic A, Gundy S, Hansteen IL, Knudsen LE,

¹ Excerpts or the complete publication have been provided to members of the Carcinogen Identification Committee, in the order in which they are discussed in this document.

Dobrovolsky VN, Boctor SY, Twaddle NC, Doerge DR, Bishop ME, Manjanatha MG, Kimoto T, Miura D, Heflich RH, Ferguson SA (2010). Flow cytometric detection of Pig-A mutant red blood cells using an erythroid-specific antibody: application of the method for evaluating the in vivo genotoxicity of methylphenidate in adolescent rats. *Environ Mol Mutagen* **51**:138-45.

El-Zein RA, Abdel-Rahman SZ, Hay MJ, Lopez MS, Bondy ML, Morris DL, Legator MS (2005). Cytogenetic effects in children treated with methylphenidate. *Cancer Lett* **230**:284-91.

Freeman GB, Reichelderfer D, Athey PM, Yarrington JT, Hejtmancik M, Eastin W, Vallant M, Chhabra R, Tennant RW (1998). Toxicity evaluation of methylphenidate hydrochloride in transgenic mice. *Toxicol Sci* **42**:72 (Abstract # 357).

Manjanatha MG, Shelton SD, Dobrovolsky VN, Shaddock JG, McGarrity LG, Twaddle NW, Moore MM, Mattison DR, Slikker W Jr, Morris SM (2009). Evaluation of mutagenic mode of action in Big Blue mice fed methylphenidate for 24 weeks. *Mutat Res* **680**:43-8.

Mirsalis J, Tyson K, Beck J, Loh F, Steinmetz K, Contreras C, Austere L, Martin S, and Spalding J (1983). Induction of unscheduled DNA synthesis (UDS) in hepatocytes following in vitro and in vivo treatment. *Environ Mutagen* **5**:482 (Abstract # Ef-5).

Morris SM, Dobrovolsky VN, Shaddock JG, Mittelstaedt RA, Bishop ME, Manjanatha MG, Shelton SD, Doerge DR, Twaddle NC, Chen JJ, Lin CJ, Paule MG, Slikker W Jr, Hotchkiss CE, Petibone D, Tucker JD, Mattison DR (2009). The genetic toxicology of methylphenidate hydrochloride in non-human primates. *Mutat Res* **673**:59-66.

National Toxicology Program (NTP, 1995). *Toxicology and carcinogenesis studies of methylphenidate hydrochloride (CAS No. 298-59-9) in F344 rats and B6C3F₁ mice (feed studies)*. NTP Technical Report Series No. **439**, NIH Publication No. 95-3355. U.S. Department of Health and Human Services.

National Toxicology Program (NTP, 2005). *NTP-CERHR monograph on the potential human reproductive and developmental effects of methylphenidate*. NIH Publication No. 05-4473. U.S. Department of Health and Human Services.

Oestreicher N, Friedman GD, Jiang SF, Chan J, Quesenberry C Jr, Habel LA (2007). Methylphenidate use in children and risk of cancer at 18 sites: results of surveillance analyses. *Pharmacoepepi Drug Safety* **16**:1268-72.

Ponsa I, Ramos Quiroga JA, Rabasè SM, Bausch R, Bielsa A, Ordeig MT (2009). Absence of cytogenetic effects in children and adults with attention deficit hyperactivity disorder treated with methylphenidate. *Mutat Res* **666**:44-49.

Selby JV, Friedman GD, Fireman BH (1989). Screening prescription drugs for possible carcinogenicity: Eleven to fifteen years of follow-up. *Cancer Res* **49**:5736-5747.

Walitza S, Kämpf K, Oli RG, Warnke A, Gerlach M, Stopper H (2010). Prospective follow-up studies found no chromosomal mutagenicity of methylphenidate therapy in ADHD affected children. *Toxicol Lett.* **193**:4-8.

Witt KL, Malarkey DE, Hobbs CA, Davis JP, Kissling GE, Caspary W, Travlos G, Recio L (2010). No increases in biomarkers of genetic damage or pathological changes in heart and brain tissues in male rats administered methylphenidate hydrochloride (Ritalin) for 28 days. *Environ Mol Mutagen* **51**:80-8.

Witt KL, Shelby MD, Itchon-Ramos N, Faircloth M, Kissling GE, Chrisman AK, Ravi H, Murli H, Mattison DR, Kollins SH (2008). Methylphenidate and amphetamine do not induce cytogenetic damage in lymphocytes of children with ADHD. *J Am Acad Child Adolesc Psychiatry* **47**:1375-83.